Phathom Pharmaceuticals Clarifies That Scheduled 13D Filing By Frazier Life Sciences Includes Administration Changes To Reporting Approach But Does Not Represent Reduction In Ownership Position Of Any Frazier Fund Or Person In Phantom
Author: Benzinga Newsdesk | August 20, 2025 07:07am